[b]NBS >> BREAKOUT ON NEWZZZ / Progenitor Cell Therapy, a NeoStem Company, Invited to Present at Two Conferences in September[/b]
2012-09-05 07:30 ET - News Release
NEW YORK, Sept. 5, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE:NBS) ("NeoStem" or the "Company"), a cell therapy company, today announced that Company management of a NeoStem company, Progenitor Cell Therapy ("PCT"), an internationally recognized contract development and manufacturing organization (CDMO), has been invited to present on its core expertise in development of commercial manufacturing processes for cell therapy at two cell therapy conferences in September. At each, PCT will offer its unique perspective as an industry leader in contract development and manufacturing of cell therapy products, with over 12 years of exclusive cell-therapy focused experience.
Timothy Fong, Ph.D, M.B.A, PCT's Vice President, Technology and Product Development, will be sharing PCT's expertise in cell therapy manufacturing with a focus on commercialization. At IBC Life Sciences' Cell Therapy Bioprocessing Conference, he will chair a panel on quality assurance and controls and will give a presentation entitled "From Concept to Product: Considerations for Developing a Robust Commercial Manufacturing Process", which will include considerations for developing a robust commercial manufacturing process. He will also speak at the Stem Cells USA and Regenerative Medicine Congress on "Cell manufacturing considerations for first-in-world stem cell therapeutics".
Dr. Fong stated, "As a cell therapeutic progresses from concept to product, the development of a commercial manufacturing process may contain unexpected technical and quality issues. The development path should follow several defined steps. My presentations will discuss the key steps in the process and highlight critical areas that need to be addressed to develop a successful commercial manufacturing process. PCT helps clients bridge the gap between discovery and patient care through efficient transfer of cell-based therapies from laboratory into clinical practice."
NeoStem and PCT invite you to attend the conference(s), see Dr. Fong's talks, and connect with the PCT team at PCT's booths. If you are a colleague of PCT or NeoStem, PCT can offer you a registration discount. Please contact PCT at bdm@pctcelltherapy.com for more details.
IBC Life Sciences' 2nd Annual Cell Therapy Bioprocessing Conference
Date: September 12, 2012, 3:30 PM EDT
Venue: DoubleTree Crystal City Hotel, Arlington, VA
Presenter: Timothy Fong, Ph.D., M.B.A., PCT's Vice President, Technology and Product Development
Terrapinn 4th Annual Stem Cells USA and Regenerative Medicine Congress
Date: September 21, 2012, 11:30 AM EDT
Venue: The Charles Hotel, Boston, MA
Presenter: Timothy Fong, Ph.D., M.B.A., PCT's Vice President, Technology and Product Development
About NeoStem, Inc.
NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a large role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT") with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.
Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic, AMR-001, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSELTM Technology platform as well as our mesenchymal stem cells product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a patent and patent pending (IP) portfolio, we believe we are well positioned to succeed.
For more information on NeoStem, please visit www.neostem.com. For more information on PCT, please visit www.pctcelltherapy.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's or its partners' successful development of AMR-001 and other cell therapeutics, the size of the market for such products, its competitive position in such markets, the Company's ability to successfully penetrate such markets and the market for its CDMO business, and the efficacy of protection from its patent portfolio, as well as the future of the cell therapeutics industry in general, including the rate at which such industry may grow. Forward looking statements also include statements with respect to satisfying all conditions to closing the disposition of Erye, including receipt of all necessary regulatory approvals in the PRC. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors, including but not limited to (i) the Company's ability to manage its business despite operating losses and cash outflows, (ii) its ability to obtain sufficient capital or strategic business arrangement to fund its operations, including the clinical trials for AMR-001, (iii) successful results of the Company's clinical trials of AMR-001 and other cellular therapeutic products that may be pursued, (iv) demand for and market acceptance of AMR-001 or other cell therapies if clinical trials are successful and the Company is permitted to market such products, (v) establishment of a large global market for cellular-based products, (vi) the impact of competitive products and pricing, (vii) the impact of future scientific and medical developments, (viii) the Company's ability to obtain appropriate governmental licenses and approvals and, in general, future actions of regulatory bodies, including the FDA and foreign counterparts, (ix) reimbursement and rebate policies of government agencies and private payers, (x) the Company's ability to protect its intellectual property, (xi) the company's ability to successfully divest its interest in Erye, and (xii) matters described under the "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company's other periodic filings with the Securities and Exchange Commission, all of which are available on its website. The Company does not undertake to update its forward-looking statements. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
CONTACT: Trout Group
Gitanjali Jain Ogawa, Vice President
Phone: +1-646-378-2949
Email: gogawa@troutgroup.com
NBS BREAKOUT ON NEWZZZ / Progenitor Cell Therapy, a
Top 10 Most Recent News Articles
Travel Awards Spotlight Luxury Hospitality's Reach
Hong Kong’s awards roll call reads less like a scorecard than a map of where premium travel wants its money and attention to go next. The 2026 World’s Travel & Hotel Awards, released November 20, cast a very wide net: heritage palaces, city hotels, beach retreats, airlines, cruise operators, tourism boards, restaurants, serviced apartments and a fair number of...
Continue Reading
COP31 Tests Whether Climate Warnings Move Power Systems
A weather alert that never reaches the control room is just expensive wallpaper. That was the useful, unsentimental thread running through a COP31 side event in Ankara on November 13: climate diplomacy is not worth much if grid operators, project owners and financiers do not change what they do when the forecast turns ugly. Implementation Means Changing Operations COP31...
Continue Reading
iHeart's 65% Plunge Brings a Fraud Probe Into Focus
November 10 did not merely bruise iHeartMedia shareholders; it left the stock closing at $0.61 after a decline of more than 65%. That kind of move gets everybody’s attention, including plaintiffs’ lawyers, and Wolf Haldenstein Adler Freeman & Herz LLP has opened an investigation into potential securities fraud claims involving iHeartMedia, its officers, and its...
Continue Reading
Healthcare's Prevention Puzzle Needs Better Incentives
When Savings Belong to the Next Plan A patient changing insurance plans can turn prevention into nobody’s asset. That is the uncomfortable little engine inside Russell Greenfield’s recent argument: an insurer may pay today for a program that helps prevent chronic illness, only to watch the eventual savings land with another plan after the member moves on. The person...
Continue Reading
Zensar’s AI Forum Puts Operations Before the AI Hype
Johannesburg’s AI conversation seems to be shedding its costume jewelry at last. Zensar’s invitation-only CIS Converge 2026 forum, held on November 20, put the attention where it belongs: not on breathless demos, but on whether companies can turn AI into sturdier operations, better customer experiences, and something resembling a measurable return. That is a healthier...
Continue Reading
FFR Adds Academic and Commercial Muscle to Its Board
Robotics boards can get crowded with lofty nouns fast, and FFR just added another one with some real-world connective tissue behind it. Carolyn Kissane, associate dean at NYU's Center for Global Affairs, has joined as an independent director. The appointment is not a product launch, a contract, or revenue. It is a governance move. Still, in a business trying to weld...
Continue Reading
OU's $44.3M Rural Care Plan Targets Oklahoma Care Gaps
A Long Drive Is a Brutal Barrier to Care Seventy-five of Oklahoma's 77 counties sit in health professional shortage territory, a figure that ought to stop people cold. It means at least 3,500 patients per provider in those counties. That is not some abstract planning headache. It is the pregnant patient delaying a specialist visit, the family weighing an ambulance ride,...
Continue Reading
Mason Adds Nonprofit Expertise to Institutional Bench
Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...
Continue Reading
Chicago Kertész Show Puts Photography's Quiet Giant First
A fork, a plate, and a sharp eye can outlast plenty of louder art. Leica Gallery Chicago is putting that proposition on the wall with André Kertész: The Master, opening December 4, 2026 and running through January 17, 2027. More than thirty signature works is not a sprawling museum survey, and frankly that may be the point. Kertész did not need grand scale to make his...
Continue Reading
AI Shopping Answers Are Becoming Retail's New Shelf
Retail’s front door is quietly being moved by a machine, and plenty of big chains appear to be staring at the old entrance. Bain’s latest work lands on an uncomfortable point: owning market share does not guarantee a retailer gets named when an AI assistant answers a shopper’s question. That ought to rattle management teams more than the usual holiday-season...
Continue ReadingTop 5 Most Recently Viewed Articles
Latham Plunge Pools Earns Top Honors as Innovative Retail Design
Latham Plunge Pools: Celebrating Innovation in Outdoor Living Latham Group, Inc. (NASDAQ:SWIM), the leading designer and manufacturer of in-ground swimming pools, has recently been recognized for its exceptional contribution to the backyard experience. Their latest achievement, the "Most Innovative Product for Retailers" award, was proudly received at the prestigious...
Continue Reading
HF Sinclair Corporation Announces Upcoming Earnings Webcast
HF Sinclair Corporation Earnings Announcement HF Sinclair Corporation (NYSE: DINO) is preparing to share its financial results for the third quarter, which ends on September 30, 2024. This important announcement is set for October 31, 2024, and will take place before the market opens on the NYSE. Details of the Earnings Release All investors and interested individuals...
Continue Reading
Verde Resources Unveils VerdePlus, Paving the Way for Green Infrastructure
Verde Resources Inc. Introduces VerdePlus for Sustainable Solutions Verde Resources Inc. (OTCQB: VRDR) is proud to announce a transformative step in their efforts towards sustainable infrastructure with the launch of VerdePlus Inc. This innovative subsidiary, developed through a partnership with Nature Plus Inc. (NPI), aims to set new standards in low-carbon construction...
Continue Reading
East Palestine Settlement Center Closure: What You Need to Know
Important Closure of the East Palestine Settlement Center The East Palestine Settlement Center, specifically created to aid those affected by a recent train derailment, will be closed on Friday, January 17. This decision comes in response to pending traffic restrictions expected in the surrounding area, which may hinder access to the facility. Rescheduling and Future...
Continue Reading
Aditx Therapeutics Faces Challenges with Stock at $0.18 Low
Aditx Therapeutics Faces Significant Stock Decline Aditx Therapeutics Inc (ADTX) has recently encountered a challenging period as its stock price plummeted to a 52-week low of $0.18. This significant decrease illustrates a dramatic 1-year change of -99.9%. Such a downturn highlights the tumultuous state of the biotech company, which is currently grappling with a market...
Continue Reading